CAM
VKTX icon

ClariVest Asset Management’s Viking Therapeutics VKTX Stock Holding History

ClariVest Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.7M Hold
32,012
– – 0.17% 167
2024
Q2 		$1.7M Buy
32,012
+22,642
+242% +$1.48M 0.17% 167
2024
Q1 		$768K Buy
+9,370
New +$417K 0.08% 310

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

ClariVest Asset Management's VKTX Position: Q3 2024 in Review

ClariVest Asset Management held its Viking Therapeutics (VKTX) position steady in Q3 2024 at 32,012 shares worth $1.7M. The position accounts for 0.17% of the portfolio, ranked #167.

ClariVest Asset Management first reported a position in VKTX in Q1 2024 and has held it in 3 quarters since. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

  • ClariVest Asset Management held 32,012 shares of Viking Therapeutics worth $1.7M as of Q3 2024.
  • ClariVest Asset Management left its Viking Therapeutics share count unchanged in Q3 2024.
  • Viking Therapeutics made up 0.17% of ClariVest Asset Management's portfolio in Q3 2024, its #167 holding.
  • ClariVest Asset Management first reported a position in Viking Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • 422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.